Floatz logo

hbi0101 cart

Antiphospholipid Antibody Syndrome

Polina StepenskyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Antiphospholipid Antibody Syndrome cohort.

Asset / SponsorPhaseRating
WARFARIN
Seoul National University Hospital
Phase 4BB
Rivaroxaban
University College, London
Phase 2B
Bcma-Cd19 Ccar T Cells
Peking University People's Hospital
Phase 2CCC
FILGRASTIM
Johns Hopkins University
N/AD
Cyclophosphamide
Johns Hopkins University
N/AD

Same molecule, other indications

hbi0101 cart is also rated in:

plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →
AL amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →